Form 4: 89bio Director Charles McWherter Executes Stock Transactions

Director Charles McWherter of 89bio, Inc. engaged in multiple stock transactions, acquiring and disposing of shares on January 21st and 22nd, 2025.

Summary

• Charles McWherter, a director at 89bio, Inc., has reported changes in his beneficial ownership of the company's stock.
• On January 21, 2025, McWherter purchased 5,000 shares of common stock at a price of $6.55 per share and disposed of 15,000 shares.
• On January 22, 2025, he purchased an additional 10,000 shares at a weighted average price of $6.71 per share, with individual transactions ranging from $6.70 to $6.72, and disposed of 25,000 shares.
• Following these transactions, McWherter's direct ownership of 89bio stock has changed.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions by a company director, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transactions are typical for directors who may be adjusting their holdings for various reasons, including personal financial planning or company stock option exercises.
• Comparable companies in the biotech sector also have directors who regularly file Form 4s, reflecting similar trading patterns.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, as insider trading activity is often monitored by investors.

Key Dates

Keywords

89bio, stock transactions, beneficial ownership, director, insider trading, ETNB, common stock